Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease

NCT04145037 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
8
Enrollment
INDUSTRY
Sponsor class

Stopped This study was voluntarily terminated by the sponsor to halt development and was not based on any safety or medical reasons.

Conditions

Interventions

Sponsor

AVROBIO